Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules
- 14 September 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (18) , 5469-5479
Abstract
Purpose: To demonstrate that a mathematical model can be used to quantitatively understand tumor cellular dynamics during a course of radiotherapy and to predict the likelihood of local control as a function of dose and treatment fractions. Experimental Design: We model outcomes for early-stage, localized non–small cell lung cancer (NSCLC), by fitting a mechanistic, cellular dynamics-based tumor control probability that assumes a constant local supply of oxygen and glucose. In addition to standard radiobiological effects such as repair of sub-lethal damage and the impact of hypoxia, we also accounted for proliferation as well as radiosensitivity variability within the cell cycle. We applied the model to 36 published and two unpublished early-stage patient cohorts, totaling 2,701 patients. Results: Precise likelihood best-fit values were derived for the radiobiological parameters: α [0.305 Gy−1; 95% confidence interval (CI), 0.120–0.365], the α/β ratio (2.80 Gy; 95% CI, 0.40–4.40), and the oxygen enhancement ratio (OER) value for intermediately hypoxic cells receiving glucose but not oxygen (1.70; 95% CI, 1.55–2.25). All fractionation groups are well fitted by a single dose–response curve with a high χ2 P value, indicating consistency with the fitted model. The analysis was further validated with an additional 23 patient cohorts (n = 1,628). The model indicates that hypofractionation regimens overcome hypoxia (and cell-cycle radiosensitivity variations) by the sheer impact of high doses per fraction, whereas lower dose-per-fraction regimens allow for reoxygenation and corresponding sensitization, but lose effectiveness for prolonged treatments due to proliferation. Conclusions: This proposed mechanistic tumor-response model can accurately predict overtreatment or undertreatment for various treatment regimens. Clin Cancer Res; 23(18); 5469–79. ©2017 AACR.Keywords
All Related Versions
This publication has 74 references indexed in Scilit:
- Stereotactic body radiotherapy for colorectal liver metastasesCancer, 2011
- Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of HypoxiaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic Ablative Radiotherapy Should Be Combined With a Hypoxic Cell RadiosensitizerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Stereotactic body radiation therapy: The report of AAPM Task Group 101Medical Physics, 2010
- Predicting Outcomes in Cervical Cancer: A Kinetic Model of Tumor Regression during Radiation TherapyCancer Research, 2010
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatmentBlood, 2009
- Pathways of DNA Double-Strand Break Repair during the Mammalian Cell CycleMolecular and Cellular Biology, 2003
- Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinomaCancer, 1998
- The linear-quadratic formula and progress in fractionated radiotherapyBritish Journal of Radiology, 1989
- Variations in Radiosensitivity of a Mammalian Cell Line with Phase of the Growth CycleNature, 1964